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Foreword by the Home Secretary
The harms caused by drug misuse are far-
reaching and affect our lives at every level. 
It includes crime committed to fuel drug 
dependence; organised criminality, violence 
and exploitation which goes hand in hand with 
production and supply; and the irreparable 
damage and loss to the families and individuals 
whose lives it destroys. 
In 2010, we set out a clear and balanced 
approach to tackle drugs. We put local 
communities at the heart of the public health 
agenda, giving local government the freedom, 
responsibility and funding to develop their 
own ways of improving public health in the 
local population. We also shifted our focus 
to recovery, recognising the wider support 
needed to achieve and sustain a life free 
from drugs and crime. But there is an urgent 
need to go further to address these harms 
and the underlying factors that can lead to 
drug misuse. This must be done alongside 
action to tackle the evolving threats from new 
drugs markets and patterns of use that are 
ever changing and often targeted at the most 
vulnerable in society. We must continue to act, 
and we must act now to build a safer, healthier 
society: one that works for everyone.  
The solutions to these challenges are grounded 
in a smarter, more coordinated approach which 
complements wider cross-government action. 
To develop this, we have engaged extensively 
with key partners in the drugs field, including 
health and justice practitioners, commissioners, 
academics and service users, as well as our 
independent experts, the Advisory Council on 
the Misuse of Drugs (ACMD). I am grateful for 
the invaluable input received. 
This Strategy sets out clear expectations for 
action from a wide range of partners, including 
those in education, health, safeguarding, 
criminal justice, housing and employment. 
It also outlines the action that we will take at a 
national level to support local areas to ensure 
everyone plays their role in:
 √ preventing people – particularly young 
people – from becoming drug users in 
the first place; 
 √ targeting those criminals seeking to 
profit from others’ misery and restricting 
the availability of drugs; 
 √ offering people with a drug dependence 
problem the best chance of recovery 
through support at every stage of their 
life; and
 √ leading and driving action on a global 
scale.  
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By working together, we can achieve a society 
that works for everyone and in which every 
individual is supported to live a life free from 
drugs, fulfil their potential and enjoy a brighter 
future for themselves and their families.
The Rt Hon Amber Rudd MP
Home Secretary
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Introduction
The complexity and pervasiveness of drug 
misuse and the harms it causes means that 
no one can tackle it alone. Government at 
both national and local levels, international 
partners, the voluntary and community sector 
and the public all have a role to play. It is vital 
that we do this together using a coordinated, 
partnership-based approach that recognises 
the common goals we all share – to build a 
fairer and healthier society, to reduce crime, 
improve life chances and protect the most 
vulnerable. 
The social and economic cost of drug supply 
in England and Wales is estimated to be £10.7 
billion a year – just over half of which (£6 billion) 
is attributed to drug-related acquisitive crime 
(e.g. burglary, robbery, shoplifting).1 As set out 
in our Modern Crime Prevention Strategy2, 
drug-related and drug-enabled activities are 
key drivers of both new and traditional crime: 
the possession of illicit substances; the crimes 
committed to fund drug dependence; the 
production and supply of harmful substances 
perpetrated by serious and organised criminals 
alongside drug market violence associated 
with human trafficking and modern slavery3. 
Drugs can also play a part in facilitating child 
sexual exploitation and abuse4 and the illicit 
use of drugs in prisons is a driver of rising 
violence, self-harm and suicide5. 
In 2015-16, around 2.7 million (8.4%) 16-59 
year olds in England and Wales reported using 
a drug in the last year, a proportion which has 
reduced over the last decade but remained 
stable over the last seven years.6 The trend is 
similar for younger people, but the proportion 
of them taking drugs is higher – 18% of 16-24 
year olds in 2015-16.
The picture for use of individual drugs is more 
varied. Cannabis remains the drug most likely 
to be used by 16-59 year olds (6.5% of this 
age group report having used this drug in 
the past year) and use of cannabis is lower 
than a decade ago and stable since 2009- 
2010. However, estimates of ecstasy use 
among those aged between 16-24 years have 
increased and in 2015-2016 they were similar 
to the level 10 years ago (4.5% in 2015-2016 
compared with 4.3% in 2005-2006).
The Government remains vigilant of new and 
emerging patterns of drug use. While use of 
new psychoactive substances among the 
general population is low (0.7% of 16-59 year 
olds reported having used a new psychoactive 
substance in 2015-2016), they continue to 
appear rapidly on the market, and use among 
certain groups is problematic, particularly 
among the homeless population and in 
prisons. In addition, there is emerging use 
of image and performance enhancing drugs 
(including intravenous use); and use of multiple 
drugs (‘poly-substance misuse’) at the same 
time poses an evolving challenge.
In 2015-16, 203,808 people received 
treatment for drug misuse. Fewer drug users 
are coming into treatment and in particular 
the number of people aged under 25 entering 
treatment for the first time who use opiates, 
mainly heroin, has fallen substantially over the 
course of the last 10 years. 
While there are more adults leaving treatment 
successfully now compared to 2009-107, 
the rates of success vary by a factor of five 
between the best and poorest performing 
local authorities8. In recent years the national 
rates have also levelled off, with a decline in 
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the proportion of opiate users completing 
treatment. This decline and local variations 
in treatment outcomes are likely to be in part 
because many of those who now remain 
in treatment for opiate use are older, often 
have health and mental health problems 
and entrenched drug dependence. Within 
the context of these problems, effective 
partnership working between health and social 
care, the criminal justice system, housing and 
employment support is essential to deliver the 
Strategy’s aims.
Linked to this ageing cohort, we have seen a 
dramatic and tragic increase in drug misuse 
deaths since 2012.9 In England and Wales, the 
number of deaths from drug misuse registered 
in 2015 increased by 10.3% to 2,479. This 
follows an increase of 14.9% in the previous 
year and 19.6% the year before that. Deaths 
involving heroin, which is involved in around 
half the deaths, more than doubled from 2012 
to 2015.
Drug misuse is common among people with 
mental health problems: research indicates 
that up to 70% of people in community 
substance misuse treatment also experience 
mental illness and there is a high prevalence 
of drug use among those with severe and 
enduring conditions such as schizophrenia 
and personality disorders. We are clear that 
reducing the harms caused by drugs needs to 
be part of a balanced approach. This means 
acting at the earliest opportunity to prevent 
people from starting to use drugs in the first 
place and prevent escalation to more harmful 
use, as well as providing evidence-based 
treatment options that can be tailored to 
individual need, to provide people with the best 
chance of recovery. We know that people with 
co-occurring substance misuse and mental 
health conditions are too often unable to 
access the care they need. We want everyone 
across the country to get the help, treatment 
and support they need to live a drug-free life 
and this Strategy sets out how we will seek to 
tackle this.
So there is much further to go. This Strategy 
sets out how we and our partners, at local, 
national and international levels, will take new 
action to respond to these challenges by:
 √ taking a smarter, coordinated 
partnership approach;
 √ enhancing our balanced response 
across the four core strands of the 
Strategy (reducing demand, restricting 
supply, building recovery and global 
action);
 √ expanding on the two overarching 
aims of the 2010 Strategy: to reduce 
illicit drug use and increase the rate 
of individuals recovering from their 
dependence by going further to 
measure both the frequency and type 
of drug used, and using recovery data 
to segment the treatment population, to 
better personalise support and recovery 
ambitions;
 √ developing a new set of measures 
to better capture the joint ownership 
required to drive action across local 
authorities, health, employment, housing 
and criminal justice partners; and
 √ providing stronger governance for 
delivering the Strategy, including a 
Home Secretary chaired Board and 
the introduction of a national Recovery 
Champion. 
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Our aims
Our ambition is for fewer people to use drugs 
in the first place, but for those that do - and 
who then experience problems - we want to 
help them to stop and to live a life free from 
dependence. Our overall aims therefore remain 
to reduce all illicit and other harmful drug 
use, and increase the rate of individuals 
recovering from their dependence. But we 
want to go further, and achieve our greater 
ambition both for progress against these aims 
as well as against a broader set of indicators 
which reflect the partnership approach that 
needs to be taken to tackle drug misuse and 
its harms. 
1. Reduce illicit and other harmful drug use
• In addition to overall prevalence, we will 
measure frequency (e.g. monthly) and 
type of drug use (e.g. opiates and crack) 
to provide an additional perspective on 
some of the most problematic drug use. 
• Where possible we will provide this data 
both at national and local levels in order 
to track progress and enhance local 
understanding and efforts to tackle drug 
use.
2. Increase the rates recovering from their 
dependence
• This is currently measured by the 
proportion of clients leaving treatment 
free from dependence and not returning 
for six months. We will go further 
and expand the measure to also 
capture those sustaining freedom from 
dependency for twelve months.
• We will segment this data to provide 
an enhanced picture of the treatment 
population and track progress for those 
that evidence tells us10 we can expect 
higher recovery rates for (e.g. newer 
opiate users and non-opiate users).
• We will provide a breakdown of what 
proportion of the most problematic drug 
users are accessing treatment and how 
long they have to wait in doing so, to 
ensure that we are reaching those who 
need support.
Drug misuse causes a wide range of social 
and health harms and costs. It is both a cause 
and consequence of wider factors including 
physical and mental ill-health, problems relating 
to employment, housing, family life and crime 
issues.11 To reflect this we will track progress 
against a broader set of new jointly owned 
measures, which complement delivery of our 
two overarching aims. These will reflect the 
joint responsibilities of the range of partners 
needed including health, housing services, 
employment support providers and criminal 
justice partners.
Our approach
Our approach is balanced over four key themes: 
 n Reducing Demand
We will take action to prevent the onset of drug 
use, and its escalation at all ages, through 
universal action combined with more targeted 
action for the most vulnerable. This includes 
placing a greater emphasis on building 
resilience and confidence among our young 
people to prevent the range of risks they 
face (e.g. drug and alcohol misuse, crime, 
exploitation, unhealthy relationships). 
 n Restricting Supply
We will take a smarter approach to 
restricting the supply of drugs: adapting 
our approach to reflect changes in criminal 
activity; using innovative data and technology; 
taking coordinated partnership action to tackle 
drugs alongside other criminal activity.
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 n Building Recovery
We will raise our ambition for full recovery  
by improving both treatment quality and 
outcomes for different user groups; ensuring 
the right interventions are given to people 
according to their needs; and facilitating the 
delivery of an enhanced joined-up approach to 
commissioning and the wide range of services 
that are essential to supporting every individual 
to live a life free from drugs.
 n Global Action
We will take a leading role in driving 
international action, spearheading 
new initiatives e.g. on new psychoactive 
substances, sharing best practice and 
promoting an evidence-based approach to 
preventing drug harms.  
Evidence
We are committed to grounding our approach 
in the latest available evidence. The Evaluation 
of the 2010 Drug Strategy12 has contributed 
greatly to the evidence base for this Strategy 
and we will continue to monitor evidence 
from around the world to understand how 
we can best respond to the challenges that 
drugs present to the UK and our international 
partners. The advice of the Advisory Council on 
the Misuse of Drugs (ACMD) is fundamental to 
informing our approach and we will continue to 
seek their valuable input and advice.  
Public Health England (PHE) also has an 
important role in developing and publishing 
the evidence base to galvanise progress 
on improving the public’s health. It recently 
published an evidence review of the outcomes 
that can be expected of drug misuse 
treatment in England, which has informed the 
development of this strategy13.
Alcohol 
While the focus of this Strategy is on drugs, 
we recognise the importance of joined-up 
action on alcohol and drugs, and many areas 
of the Strategy apply to both, particularly 
our resilience-based approach to preventing 
misuse and facilitating recovery. Alcohol 
treatment services should be commissioned 
to meet the ambitions set out in the Building 
Recovery chapter that are relevant to them, 
and in line with the relevant NICE Alcohol 
Clinical Guidelines14,15. Commissioning of 
alcohol and drug treatment services should 
take place in an integrated way, while 
ensuring an appropriate focus on alcohol or 
drug specific interventions, locations, referral 
pathways and need.
In addition, local authority public health 
teams should take an integrated approach 
to reducing a range of alcohol related harm, 
through a combination of universal population 
level interventions and interventions targeting 
at risk groups. The Modern Crime Prevention 
Strategy 2016 highlights alcohol – as with 
drugs – as a key driver of crime and sets out a 
range of actions to tackle alcohol-driven crime. 
UK coverage of the Drug Strategy 
The legal framework relating to the misuse 
of drugs, including the Misuse of Drugs Act 
1971 and the Psychoactive Substances Act 
2016, is reserved to the UK Government. 
The UK devolved administrations have their 
own approaches to tackling drug and alcohol 
misuse and dependence in areas where 
responsibility is devolved.16,17,18. Some of the 
policy areas covered by this Strategy such 
as healthcare, education, housing and social 
care therefore only cover England. The areas 
relating to the work of the police and the 
criminal justice system apply to England and 
Wales and the work of the Department for 
Work and Pensions to England, Scotland and 
Wales. 
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1. Reducing Demand
This Government is clear that in order to 
protect society and individuals from the harms 
of drug misuse, we must act at the earliest 
opportunity to prevent people starting to use 
drugs in the first place, and prevent escalation 
to more harmful use. Building on the evidence 
set out in the ACMD report, Prevention of 
drug and alcohol dependence19, we set out 
the action needed at national and local levels 
to ensure an effective universal approach to 
preventing drug use, combined with targeted 
action for those most at risk.
A universal approach across 
the life-course 
We are committed to giving everyone the best 
start in life and ensuring each person can fulfil 
their full potential. This starts with universal 
action to promote health and wellbeing and 
to build resilience and confidence in young 
people, in partnership with them, which is 
complemented by drug and alcohol specific 
resources for use in universal settings. 
PHE will support local areas to take action to 
improve health and wellbeing across the life-
course, including:  
•  providing professional guidance for 
midwives, health visitors and school 
nurses under the Healthy Child 
Programme; 
•  providing support and guidance to local 
authorities, including systems to support 
integrated commissioning and service 
delivery, from conception to the age of 
five;
•  providing support to school nurses, 
teachers and wider community 
services including youth workers to 
work together to promote health and 
wellbeing; and
• providing information and intelligence 
to improve decision-making, enabling 
high quality and cost effective services, 
through the National Child and Maternal 
Health Intelligence Network, including 
child health profiles.20
Building confidence and resilience 
Schools have a key role to play in helping 
children and young people to develop the 
confidence and resilience needed to support 
academic attainment, to be valued by 
employers, and to make a positive contribution 
to British society. High quality Personal, Social, 
Health and Economic (PSHE) education is at 
the heart of supporting young people to leave 
school prepared for life in modern Britain. This 
means investing in a range of evidence-based 
programmes, which have a positive impact 
on young people and adults, giving them 
confidence, resilience and risk management 
skills to resist risky behaviours and recover 
from set-backs. The Children and Social Work 
Act provides powers for the Secretary of State 
for Education to make PSHE, or elements 
therein, mandatory in all schools, subject to 
careful consideration. The Department for 
Education will engage widely on the scope and 
content of the subject to further support the 
development of knowledge for all children and 
young people in this area.
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• We will encourage schools and teachers 
and school nurses to develop their 
practice with the support of specialist 
organisations and expert professionals. 
For example, the PSHE Association 
has produced a suggested programme 
of study as guidance for teachers, and 
continues to provide wider support by 
highlighting other sources of expertise. 
It also provides a quality assurance 
service for other providers of resources, 
further strengthening the confidence of 
teachers when selecting appropriate 
materials.
We will encourage the use of prevention 
strategies at primary and secondary school, 
such as the ‘Get Set for the Spirit of Sport’ 
campaign, to provide teachers with resources 
to encourage young people to develop a core 
set of values that enables them to make the 
right decisions in and out of sport, including 
avoiding substance misuse. 
Dedicated drug and alcohol resources 
We are clear that programmes that are least 
effective in preventing substance misuse 
are those that focus solely on scare tactics, 
knowledge-only approaches, mass media 
campaigns or the use of ex-users and the 
police as drug educators in schools, where 
their input is not part of a wider evidence 
based prevention programme.21 
In line with our broad approach to prevention 
and resilience building, we will support 
commissioners, schools, educators and 
prevention practitioners to take an evidence-
based approach to preventing substance 
misuse. We will:  
• develop our Talk to FRANK service so 
that it remains a trusted and credible 
source of information and advice for 
young people and (concerned) others;
• expand the Alcohol and Drugs Education 
and Prevention Information Service 
(ADEPIS) to reach wider prevention 
partners e.g. youth offending teams; 
• continue to update our New 
Psychoactive Substances Resource 
Pack for educators;
• continue to develop and promote the 
‘Rise Above’ digital hub, that uses 
interactive and engaging content to 
delay and prevent young people from 
engaging in exploratory behaviours 
(smoking, drinking alcohol, substance 
misuse and risky sexual practices). By 
tackling multiple behaviours, it aims 
to build and improve the all-round 
resilience of young people so they are 
able to avoid risky behaviours;
• monitor existing programmes, both here 
and overseas, to share the evidence 
and to identify future initiatives to help 
prevent substance misuse and crime, for 
example the two year trial of the Good 
Behaviour Game initiative, being run by 
Mentor UK; and
• promote the European Drug Prevention 
Quality Standards22 (EDPQS) principles 
to help partners develop and assess the 
quality of drug prevention initiatives. 
Colleges, universities and other education 
providers and settings also have a key 
role to play as they work with millions of 
young people and young adults at a critical 
transition period in their lives. Universities 
take their responsibilities seriously with most 
institutions offering support to students as 
part of wider health and welfare services. For 
example, programmes such as UK Anti-
Doping’s Clean Sport University Accreditation 
Scheme promote drug prevention by instilling 
a positive healthy living and drug-free culture 
for students, staff, and the public who utilise 
campus facilities. The UK National Healthy 
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Universities Network supports university 
approaches to health and wellbeing and 
aims to promote student wellbeing including 
concerning substance misuse.23
Parents, families and friends also play 
an integral role in preventing substance 
misuse and supporting those with a 
dependency towards recovery. We will ensure 
these resources are available to all those 
concerned, enabling them to access the 
advice and support they need.   
Alcohol and Drug Education and 
Prevention Information Service
ADEPIS is a platform for sharing evidence-
based information and resources aimed 
at schools, practitioners working in 
prevention, and a growing range of other 
settings for reaching young people. 
Since its launch in 2013, ADEPIS has 
become acknowledged as the leading 
source of evidence-based information and 
resources for alcohol and drug education 
and prevention. Mentor UK was recently 
awarded a new three year contract to 
continue to develop and deliver the 
programme for schools and community 
prevention services. Since April 2015, 
ADEPIS also includes the Centre for 
Analysis of Youth Transitions, a repository 
of preventative interventions. 
A targeted approach for high 
priority groups 
In addition to universal preventative action, a 
more targeted approach is needed for those 
most at risk of misusing drugs and to tackle the 
threats of new types of drug misuse. We have 
set out below our assessment of new trends and 
challenges and national action. Local areas are 
best placed to understand their local needs and 
the services required. We expect local partners 
and agencies to identify groups at risk in their 
communities and take appropriate action. We 
will further support this through provision of local 
needs assessment data, tools and guidance to 
help better target these populations. 
Vulnerable young people 
We know that young people’s drug misuse 
overlaps with a range of other vulnerabilities, 
which can also exacerbate their risk of abuse 
and exploitation. In 2015-16, 17% of the 
young people accessing specialist substance 
misuse services were not in education, training 
or employment and 12% were ‘looked after 
children’24. Local agencies including the police, 
youth offending teams, sexual health services, 
mental health services, looked after children 
teams and hospitals, should ensure that each 
interaction with vulnerable young people, 
regardless of the issue, is an opportunity for 
identification and interventions for substance 
misuse and wider problems.
Most young people who have developed 
substance misuse problems are not at the stage 
where they are dependent on drugs or alcohol 
and so require a different response, focused on 
preventing more problematic use. We also know 
that young people accessing specialist substance 
misuse services are usually experiencing 
other problems such as self-harm or other 
manifestations of poor mental health, truanting, 
offending and sexual exploitation which may be 
driving the young person’s substance misuse.
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It is critical therefore that specialist substance 
misuse services are linked with wider children’s 
services. For example, child and adolescent 
mental health services have a vital role in 
working closely with specialist substance 
misuse services and, in some areas, providing 
specialist substance interventions, both in the 
community and in residential settings. Earlier 
this year we commissioned the Care Quality 
Commission to undertake a major thematic 
review of child and adolescent mental health 
services which is expected to report in March 
2018. The review will make recommendations 
for system improvements and early findings will 
inform the evidence base for the Children and 
Young People’s Green Paper to be published 
later this year.  
Multi-agency working is crucial and should 
involve a range of local stakeholders 
including clinical commissioning groups, 
local safeguarding children boards and youth 
offending teams. We will support this at a 
national level through:
• support for Youth Offending Teams to 
work with individuals from the youth 
justice system with substance misuse 
problems and engage them in educational 
support, particularly those with special 
educational needs under the new special 
educational needs and disability reforms, 
ensuring that Education and Health Care 
Plans (drawn up by Local Authorities and 
Clinical Commissioning Groups following 
assessment) are made where assessed 
as appropriate to provide relevant 
and structured support and treatment 
interventions;
• building on the Care Leavers Strategy to 
ensure that vulnerable care leavers are 
supported to avoid a range of negative 
health outcomes, including substance 
misuse, in particular through the Children 
and Social Work Act 2017 which 
introduced a new duty on local authorities 
to extend support from a Personal 
Adviser to all care leavers to age 25; 
• working with Ofsted to ensure those 
working in services inspected and 
regulated including children’s homes, 
independent fostering agencies and 
residential schools have access to up-
to-date resources and take appropriate 
action to tackle substance misuse in the 
children they care for; 
• PHE’s review of key components of 
young people’s specialist substance 
misuse services which will assist local 
authorities to commission effective 
treatment services for young people; and
• PHE publishing a report collating the 
evidence and research on child sexual 
exploitation, to support local public 
health teams to engage in multi-agency 
responses.
Those not in education, employment
or training 
Young people who self-declare substance 
misuse are over-represented in the not in 
education, employment or training (NEETs) 
group. We are committed to reducing the 
number of young people NEET and we will:  
• continue to encourage local authorities 
and schools to use tools such as ‘risk 
of NEET indicators’ so they can support 
pupils (particularly those from vulnerable 
groups) to make good decisions; and
• continue to provide funding for a wide 
range of voluntary and community 
sector organisations that support 
children, young people and families, 
some of whom may be at risk of 
becoming NEET.
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Offenders 
Around 45% of acquisitive offences are 
committed by regular heroin/crack cocaine 
users.25 The criminal justice system provides a 
prime opportunity to tackle substance misuse 
and ensure the individual has access to the 
support they need to stop. Action to tackle 
drug misuse alongside offending is set out in 
the Restricting Supply chapter.  
Families 
We know there are families where substance 
misuse is just one of a number of other 
complex problems. Parental drug and alcohol 
dependence can have a significant impact 
on families, particularly children, and can limit 
the parent’s ability to care for their child(ren). 
Parents are role models for their children and 
parental dependence increases the likelihood 
of children misusing drugs and alcohol 
themselves. It can also mean that children take 
on inappropriate caring roles for their parents. 
Supporting vulnerable families to break inter-
generational pathways to dependence is a part 
of our approach to prevent and reduce the 
demand for drugs and to help build recovery. 
At a national level we have expanded the 
Troubled Families Programme which supports 
local areas to ensure their services take an 
integrated and co-ordinated whole family 
approach. The current programme (2015 – 
2020) now specifically supports families with 
younger children and those with a broader 
range of problems, such as substance misuse, 
domestic abuse or mental health issues.
• PHE will also work with Family Drug and 
Alcohol Courts and local public health 
teams to help them to work together 
to improve outcomes for families and 
children.
• PHE will review the evidence and 
provide advice on the estimated number 
of children likely to be affected by the 
drug and/or alcohol use of their parents, 
and provide advice to national and local 
government on where action could 
have the greatest impact on improving 
children’s outcomes.
Intimate partner violence and abuse
Research indicates that women with experience 
of extensive physical and sexual violence are 
more likely to have an alcohol problem or be 
dependent on drugs, compared to women with 
little experience of violence and abuse26.
A number of individuals in contact with drug 
and alcohol treatment may be perpetrators of 
such abuse27. Substance misuse treatment 
services can provide an opportunity to identify 
and refer victims to support and perpetrators to 
programmes to reduce their propensity to abuse. 
• We will build on work looking at the 
relationship between intimate partner 
abuse and drug misuse to support 
innovative approaches to working 
with victims and perpetrators, and 
achieve sustainable reductions in repeat 
offending and misuse. 
Sex workers 
Those selling sex are at greater risk of drug 
misuse, which can be a way of coping with what 
they are having to do, or because they are being 
coerced (into both prostitution and drug use), or 
because they became involved in prostitution to 
fund an existing drug dependence. 
As set out in the 2016 Violence Against Women 
and Girls Strategy28, we will continue to tackle 
the harm and exploitation associated with 
prostitution, including substance misuse, while 
supporting those who want to leave prostitutioni.
i While this action is covered by the Violence Against Women and Girls Strategy, our approach covers all victims, regardless of gender.
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• We will shortly be commissioning 
in-depth research to develop our 
understanding of the nature and 
prevalence of prostitution and sex work 
in England and Wales. This research will 
help support future policy development 
and ensure that our interventions are 
targeted to reduce harm.
 Homeless 
We know homelessness can be both a cause 
and consequence of drug misuse and that 
homelessness is often compounded by 
substance misuse, as well as poor physical 
and mental health.29 The most disadvantaged 
and vulnerable people in society, including 
those who are homeless, may be at greater 
risk from the most dangerous NPS. The 
longer someone experiences homelessness or 
rough sleeping the bigger the impact on their 
wellbeing, which leads to increasingly complex 
needs, such as substance misuse. Just over 
a quarter of NPS users entering treatment in 
2015-16 used them alongside opiates. Half 
of this group reported housing problems at 
the point of treatment entry - twice the level 
reported by drug users overall.30
• We have protected the homelessness 
prevention funding for local authorities, 
totalling £315m by 2019-20, and 
increased central investment for 
innovative programmes to tackle 
homelessness to £149m until the end of 
the spending review period. 
• We will work with the homelessness 
sector to address the misuse of NPS 
among the homeless population, 
including those in hostels and supported 
accommodation.
• We have launched the £50 million 
Homelessness Prevention Programme, 
which will enable local areas to develop 
an end-to-end approach to reducing 
and preventing homelessness, through 
partnership working and a holistic 
approach to support all of an individual’s 
needs. This includes:
 √ £20 million for universal homelessness 
prevention through the Prevention 
Trailblazers funding;
 √ £20 million for initiatives that provide 
targeted support for those at 
imminent risk of sleeping rough, or are 
new to the streets; and 
 √ £10 million of Social Impact Bond 
funding for rough sleepers and single 
homeless people with complex needs.
Veterans
As with civilian members of the community, 
veterans can be vulnerable to substance 
misuse.Veterans sometimes use alcohol 
and/or drugs to cope with the physical and 
psychological effects of military service. These 
risks can be increased if their physical and/
or mental health reduces their ability to find 
and hold long term, fulfilling employment and 
secure accommodation. Local public health 
teams, with support from PHE, work to ensure 
that appropriate local support is available for 
veterans with substance misuse problems.
• NHS England, PHE, Clinical 
Commissioning Groups Commissioners 
and relevant health care providers will 
continue to work together with the 
veterans community to prevent and treat 
any alcohol and drug problems. They will 
also continue to provide tailored support 
to veterans in any part of the criminal 
justice pathway: in prisons, police 
custody, courts or in the community.
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• The publication of the Defence People 
Mental Health and Wellbeing Strategy 
provides a focus on promoting positive 
mental wellbeing in all Defence People, 
preventing mental illness, reducing 
the need for medical services among 
Service Personnel, who are the veterans 
of the future. The aim is that those in 
need of mental healthcare receive timely, 
safe and effective treatment. A healthier 
Armed Forces will ensure a positive, 
long term impact on the lives of those 
that have served.
Older cohort 
The proportion of older people reporting 
substance misuse issues is increasing 31. 
This may be because people who started 
using drugs when they were younger either 
continue to misuse drugs and alcohol and 
experience more problems as they age or 
perhaps return to their misuse because of 
the challenges of ageing, including pain, 
loneliness, or depression. The average age 
of people in treatment is increasing, with 
increasing proportions in their 40s, 50s and 
60s. They need the usual health screening 
and monitoring that a non-drug user might be 
offered appropriate to their age and general 
health status, but they may also have special 
health needs due to the complications of long-
term drug (and alcohol) use and of treatment.
• The ACMD is currently looking at the 
evidence that exists around problems for 
ageing drug users (aged over 45 years). 
A Working Group has been established 
to map the numbers of older drug 
users in the UK and draw on UK and 
international evidence to establish the 
current and future needs of this cohort. 
We will give full consideration to the 
findings and recommendations from the 
ACMD once received. 
A targeted approach for 
evolving and emerging threats
New psychoactive substances
The continued emergence of NPS (eg synthetic 
opioids) – the content and harms of which 
are not known due to their rapidly changing 
make up and/or novel patterns of use - has 
created additional dangers to some of our 
most vulnerable groups e.g. young people, 
the homeless and prisoners. We have already 
taken a range of action to reduce harms from 
the continuing evolution of these substances 
including implementation of the Psychoactive 
Substances Act 2016, development of local 
toolkits, a refreshed resource pack for educators, 
and world-leading NPS treatment guidelines. 
In addition, PHE is developing a NPS 
intelligence system, which aims to reduce the 
length of time between drug-related health 
harms emerging and effective treatment 
responses to these harms. There are two key 
components of this work:
• piloting a new system (RIDR - Report Illicit 
Drug Reactions) to collect information 
about adverse reactions and harms 
caused by NPS and other drug use; and
• establishing a NPS clinical network of 
leading clinicians and experts to analyse 
the data coming from RIDR and other 
existing drugs intelligence systems, to 
identify patterns and harms, and agree 
appropriate clinical responses to NPS 
problems.
NHS England has carried out an extensive 
review of its specification for substance 
misuse treatment in prisons and consequently 
increased the focus of provision on NPS. 
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Chemsex 
Chemsex is a term for the use of drugs 
before or during planned sexual activity to 
sustain, enhance, disinhibit or facilitate the 
experience. Chemsex commonly involves crystal 
methamphetamine, GHB/GBL and mephedrone, 
and sometimes injecting these drugs (also 
known as slamming). Chemsex carries serious 
physical and mental health risks including the 
spread of blood borne infections and viruses. 
• PHE will support local areas to meet 
these needs by promoting and 
publishing guidance on effective 
practice, including targeted interventions 
and close collaboration between sexual 
health services and other relevant 
services including community groups.
Image and performance enhancing 
drugs
The use of image and performance enhancing 
drugs (IPEDs) continues to be of concern. 
Those that use these substances tend not 
to identify as drug users but put themselves 
at risk of a number of health harms including 
blood borne infections and significant 
cardiovascular problems, which are potentially 
life-threatening. In addition, the content of 
these substances is often unknown due to the 
increasing availability of mislabelled products 
that are being sold by a growing counterfeit 
market, leading to further health risks.32
We are taking coordinated action working 
with key partners (ACMD, UK Anti-Doping, 
law enforcement agencies) and independent 
experts to better understand the IPED-
using population and raise awareness of the 
risks of IPED use, including the spread of 
blood borne infections; support local areas 
to respond effectively; and take action as 
necessary to disrupt the supply of IPEDs and 
any associated criminality. 
Misuse of and dependence on 
medicines
Medicines such as benzodiazepines and 
opioids can lead to dependence in patients 
if used for an extended period of time. In 
addition, some people misuse or become 
dependent on over-the-counter medicines. 
Access to medicines on the internet has led 
to increases in online purchasing, some of 
which is legitimate, but with some internet sites 
unlicensed and supplying fake or counterfeit 
medicines. 
We are working to better understand the 
problems and promote good prescribing 
practice. To protect the public, the Medicines 
and Healthcare products Regulatory Agency 
takes enforcement action against unlicensed 
websites selling medicines.
• The ACMD provided advice on the 
diversion and illicit supply of medicines 
in December 2016. The Government will 
respond to its recommendations shortly.
• We will continue to support local 
authorities and clinical commissioning 
groups so that people dependent on 
medicines can access suitable treatment.
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2. Restricting Supply
The international production and trade in 
illegal drugs is a global business controlled 
by organised criminals. Our National Security 
Strategy and Strategic Defence and Security 
Review 201533 describes serious and 
organised crime, including drug trafficking, as a 
significant threat to our national security. 
Ninety five percent of the heroin on UK 
streets originates from Afghanistan. Cocaine 
consumed in the UK comes from Peru, 
Colombia and Bolivia, and is trafficked to the 
UK direct, or through Europe, the Caribbean 
and West Africa.34 NPS are primarily imported 
from China and India. Most cannabis in the 
UK is also imported. However, the number of 
cannabis farms detected in the UK has grown 
in recent years and the level of amphetamine 
processing within the UK is increasing35.
Around a third of the organised crime groups 
(OCGs) operating against the UK are involved 
in drug trafficking36. A significant number of 
these groups are also involved in violent crime, 
including firearms offences and specialist 
money laundering. The darknet continues to 
evolve as a mechanism for the distribution 
and marketing of controlled substances. 
Foreign National Offenders (FNOs) continue to 
be engaged in serious and organised crime, 
including drug-related crimes37. A National 
Crime Agency (NCA) FNO threat desk was set 
up in September 2015. Its key aims are to drive 
up the use of immigration powers to disrupt 
individuals and to make intelligence on serious 
and organised crime activity more readily 
available to immigration decision makers. 
As described in the Serious and Organised 
Crime Strategy, our aim remains to reduce 
substantially the levels of serious and 
organised crime affecting the UK and our 
interests.38 In line with that Strategy, we will 
continue to tackle the organised criminals and 
the enablers of criminality associated with the 
trafficking and distribution of drugs. 
We recognise the changing behaviour of 
criminals and the interconnectivity between 
the illegal drugs trade and other crime types 
and our efforts to respond to the threat 
will continue to evolve accordingly. We will 
continue to support the police and NCA 
through the sharing of intelligence on emerging 
markets and changing crime types and 
develop innovative technologies to support 
enforcement activity.  We will continue to build 
on our partnerships at all levels, including with 
Police and Crime Commissioners and the 
College of Policing. The specific actions we are 
taking to achieve these objectives are set out 
below.
The legal framework
The Misuse of Drugs Act 1971 (MDA) 
continues to be the primary legislative 
framework for drug control in the UK. Following 
advice from our independent experts, the 
Advisory Council on the Misuse of Drugs 
(ACMD), the Government will continue to 
act swiftly to control substances under the 
MDA 1971 where new evidence of harms or 
potential harms emerges. 
We have no intention of decriminalising drugs. 
Drugs are illegal because scientific and medical 
analysis has shown they are harmful to human 
health. Drug misuse is also associated with 
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much wider societal harms including family 
breakdown, poverty, crime and anti-social 
behaviour. We are aware of decriminalisation 
approaches being taken overseas, but it is 
overly simplistic to say that decriminalisation 
works. Historical patterns of drug use, cultural 
attitudes, and the policy and operational 
responses to drug misuse in a country will all 
affect levels of use and harm. 
The landmark Psychoactive Substances 
Act 2016, which commenced on 26 May 
2016, completes the legislative tool kit and 
fundamentally changes the way we tackle 
the supply of psychoactive substances not 
already covered by the MDA. It removes their 
availability from open sale on the UK’s high 
streets and puts an end to the fast paced 
nature of the market. It also challenges the 
perception once and for all that so called ‘legal 
highs’ are safe. Law enforcement agencies 
now have a better range of powers to tackle 
this issue at every level in the community and 
are able to deal with the increased threat these 
substances continue to pose. 
Since the Psychoactive Substances Act 2016 
came into force, hundreds of retailers across 
the UK have either closed down or are no 
longer selling psychoactive substances; police 
have arrested suppliers; and action by the NCA 
has resulted in the removal of psychoactive 
substances being sold by UK based websites. 
Section 58 of the Psychoactive Substances 
Act 2016 commits the Home Office to review 
the operation of the Act within 30 months of 
its implementation. The review will be based 
around four key themes: enforcement, sales 
and availability, prevalence, and health and 
social harms. Using, or developing, existing 
data sources, it will examine changes in activity 
before and after the implementation of the Act, 
and also consider unintended consequences. 
The review will report its findings in late 2018.
Tackling the production and 
distribution of drugs
Overseas transit routes 
Our upstream activity to tackle overseas 
drug supply will disrupt the criminal networks 
seeking to traffic illegal drugs to the UK. 
Our approach is set out in the Serious and 
Organised Crime Strategy. We will:
• cooperate with international partners. 
The NCA’s overseas liaison network 
shares intelligence and collaborates 
with law enforcement agencies in key 
countries along the main drugs routes; 
and 
• build capacity in priority countries. We 
are working to strengthen responses 
to drug trafficking and to address the 
vulnerabilities that drive, enable and 
perpetuate it. The Conflict, Stability 
and Security Fund (CSSF) will be 
used to build capacity, particularly 
in Afghanistan, Pakistan, Nigeria, 
East Africa, the Caribbean, Peru and 
Colombia. Our capability building 
projects cover a wide range of issues 
related to the fight against narcotics, 
from anti-corruption work and improving 
border checks, through to enhanced 
investigation and prosecution practices. 
Drugs at the border 
The border represents a critical line of defence 
for identifying and disrupting illegal activity, 
including the importation and distribution of 
drugs, often with links to other serious and 
organised crime. The border is a complex 
operating environment where effective 
interventions rely on provision of data, 
intelligence sharing and ability to search 
people, vehicles and vessels. We will invest 
in detection capabilities through the use of 
targeting and technology. This will include:
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• the Advanced Freight Targeting 
Capability (AFTC) to support better 
identification of consignments deemed 
to be high risk. It will integrate a number 
of data streams, such as from carriers, 
shipping companies and hauliers, more 
effectively to make our consignment 
targeting capability more effective;
•  implementing new detection technology 
to maximise search opportunities in the 
port environment;
•  continuing to support multi-agency 
intelligence sharing, which has 
generated significant operations and 
seizures of cocaine by Border Force’s 
front line officers and maritime fleet; and
•  looking to maintain and build on the 
sharing of intelligence and operational 
capabilities between UK law 
enforcement and European partners.  
Domestic cannabis production 
Cannabis continues to be the most widely 
used illegal drug in the UK39 and the 
commercial cultivation of cannabis continues 
to pose a significant risk. A significant number 
of organised crime groups in the UK are 
engaged in commercial cultivation, using it as a 
means to fund other criminal activity, including 
money laundering, human trafficking, modern 
slavery and illegal immigration.40 Coercion and 
increasing levels of violence have also been 
attributed to cannabis cultivation. Tackling 
cannabis cultivation therefore presents the 
opportunity for law enforcement agencies to 
tackle these other priorities at the same time. 
In consultation with Government, the National 
Police Chiefs’ Council will:
• ensure that there is consistency and 
accuracy in the recording of data by 
police forces in respect of cannabis 
cultivation so that there is a clear picture 
of the scale of the problem; who is 
involved; and how they operate;
• refresh the guidance for the police on 
tackling cannabis cultivation; 
• evaluate police training on this issue, 
ensuring that they safeguard those who 
are vulnerable and consider tackling 
cannabis as a tactic to target serious 
and organised crime; and 
• seek to ensure better information 
sharing between agencies, such as 
the police, energy companies, the fire 
service and landlords.
Drugs, gangs and related exploitation 
‘County lines’ is the term used by police to 
refer to urban gangs supplying Class A drugs 
to suburban areas, rural areas, market and 
coastal towns using dedicated mobile phone 
lines (“deal lines”). Gangs typically use children 
and young people as runners to move drugs 
and money to and from the urban area and 
this often involves them being exploited 
through deception, intimidation, violence, debt 
bondage, grooming and/or trafficking by the 
gang. In addition, gangs are known to target 
and exploit vulnerable adults by taking over 
their homes to use as a local bases for drug 
dealing. 
The latest NCA assessment of county lines, 
published on 17 November 2016, provides an 
updated intelligence picture and confirms that 
the risk and threat from county lines remains 
live and growing.41 Tackling county lines is 
one of six key priorities within our approach 
to Ending Gang Violence and Exploitation and 
action on this issue includes:
• establishing a new Home Office-led 
working group to develop and deliver a 
coherent set of actions across the police 
and key sectors to tackle county lines;
• enhancing police capability to respond 
to this issue, including the introduction 
of new legislation to close down mobile 
phone lines being used for drug dealing; 
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• measures to raise awareness of the 
county lines threat amongst frontline 
staff including in education, health, 
children’s services, housing and 
jobcentre staff; and
• a further assessment of the threat from 
county lines by the NCA in 2017.
Managing information and 
intelligence 
Role of the National Crime Agency 
The NCA informs and monitors scientific 
research to enhance its capability to deliver 
innovative evidence-based disruptions to the 
trafficking of illegal drugs. The NCA monitors 
various intelligence sources and digital media 
in order to identify emerging drug trends and 
usage. Drug markets are monitored in the UK 
through drug price collections from a range 
of sources. Combined with national purity 
data collections on heroin and cocaine, this 
insight generates early warning indicators for 
new market trends, while providing important 
context for intelligence. 
In addition, the pathways into the trafficking, 
distribution and sale of illegal substances 
have been examined in the NCA Pathways 
into Serious and Organised Crime intelligence 
assessment.42 This found that pathways into 
the drug trade can be varied but noted how 
experience of drug use provides opportunities 
into wider supply; the importance of familial 
influence; and how links to source countries 
or countries of trafficking importance are 
exploited. This research can be used to plan 
interventions in line with the approach in the 
Serious and Organised Crime Strategy. 
• The NCA will report on its findings to the 
new Drug Strategy Board. 
DrugWise undertook a street drug survey to 
gather information through discussions with 
police and frontline drug workers across the 
UK. This was published in February 2017. 
It identified emerging trends on the ground 
and provided valuable additional information 
that complements our official statistics and 
research43.
The Forensic Early Warning System 
With the introduction of the Psychoactive 
Substances Act 2016, we will re- energise 
the UK’s world leading Forensic Early Warning 
System (FEWS) to meet new challenges and 
address emerging threats.
FEWS III will continue to support the 
initial operation of the 2016 Act, running 
a programme of psychoactivity testing of 
substances to support law enforcement activity 
and prosecutions.  
We will also build on the success FEWS has 
had over the last five years by continuing to 
develop the UK’s ability to gather information 
on the availability of NPS. This will include 
enhancing our understanding of NPS in the 
UK, particularly at the border, and maximising 
the use of our existing network of forensic 
providers to share intelligence and rapidly 
identify emerging psychoactive substances as 
they appear in the UK.  
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Enablers of criminality
The internet 
Like other crime types, the internet is being used 
to facilitate illegal drugs supply and evade law 
enforcement action.44 Distribution and marketing 
of controlled substances via the darknet/hidden 
internet continues to develop, with anonymous 
hosting of content, and access to this, enabled 
through software such as The Onion Router 
(TOR) browser.45 As set out in our National 
Security Strategy and Strategic Defence and 
Security Review 201546, we will take forward 
plans for a new intelligence unit dedicated to 
tackling the criminal use of the darknet, making 
it more difficult for darknet vendors to operate 
from both within and outside the UK.
Tackling drugs on the darknet
One of the darknet’s most renowned British 
vendors and his business partner were 
sentenced to a total of ten years on 29 
February 2016 after an NCA investigation 
uncovered the buying and selling of a 
catalogue of illegal drugs, including crack 
cocaine and methamphetamine. The pair 
claimed they were running a legitimate 
business selling legal highs.
Their site on the darknet specialised in 
supplying military-grade foil packaging 
that claimed to hide illegal materials from 
detection. One of the individuals was 
arrested by NCA officers in an international 
operation targeting prominent vendors on 
Silk Road 2.0, following the darknet market 
place’s takedown in late 2014. 
Officers searched the individual’s home and 
found class A and B drugs and numerous 
computers. They also seized thousands of 
Post Office receipts with customer details. 
Forensics analysis of the machines revealed 
extensive online activity, with 5,235 sales 
over two years. He had also been sending 
packages of drugs hidden on blotter paper 
into prisons.
Bribery and corruption 
Without the use of bribery and corruption as 
an enabler, serious and organised crime would 
not be able to operate to its present extent and 
scale. This includes the production, trafficking 
and distribution of illegal drugs.  For example, 
organised crime groups use corruption to 
ensure the smooth movement of drugs through 
ports and borders. Over recent years, the 
UK has taken a number of steps to deal with 
corruption and there are good structures and 
legislation in place. The Bribery Act 2010 
allows the prosecution of corporations or 
individuals who commit bribery offences. In 
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2016, the UK hosted a global Anti-Corruption 
Summit in London, agreeing a historic package 
of actions to tackle corruption in all its forms. 
Work is underway to develop and publish a 
new Anti-Corruption Strategy following a UK 
commitment made at the summit.
Money laundering 
Money laundering is a critical enabler of almost 
all serious and organised crime, including the 
drugs trade. Profit is one of the six drivers of 
crime in the Modern Crime Prevention Strategy 
and is the principal motivation for much serious 
and organised crime, with criminal enterprises 
needing money to operate. The Serious 
Crime Act 2015 implemented the Serious and 
Organised Crime Strategy commitment to 
make it harder for criminals to move, hide and 
use the proceeds of crime by strengthening 
the Proceeds of Crime Act. This made it 
easier to freeze criminal assets, to lengthen 
sentences for those who refuse to pay off 
their confiscation order and to extend the 
financial investigation powers used to trace the 
proceeds of crime.
We will radically strengthen our response 
to all forms of money laundering having 
implemented the Anti-Money Laundering and 
Counter-Terrorist Financing Action Plan which 
was published in April 2016.47 As part of that 
response, we have published the Criminal 
Finances Bill which contains measures that will 
significantly enhance our ability to seize illicit 
funds, to require those who have unexplained 
wealth to explain how they obtained it and to 
support better information sharing within the 
private sector.
Firearms 
Of the organised crime groups engaged in the 
supply of illegal drugs, a significant proportion 
is involved in violent crime, including the 
criminal use of firearms48. Where firearms are 
discharged in the UK, it is usually by urban 
street gangs and organised crime groups 
enforcing their business, which is most often 
drugs supply. Illegal firearms are highlighted by 
the NCA’s National Strategic Assessment as a 
priority threat. 49 In response, it has increased 
its focus on developing the intelligence picture 
on firearms supply and to investigating those 
criminals that seek to supply and/or use illegal 
firearms in the UK. 
• We will continue our work to choke 
off the supply and availability of illegal 
firearms, including tackling the risks 
of diversion of firearms from the 
legitimate market, to prevent their use 
by criminal or terrorist groups in the UK. 
We will ensure that we have the right 
intelligence, detection, enforcement 
capabilities policies and legislation, both 
at the UK border and within the country. 
• We will continue to work with 
international partners to tackle the illegal 
possession and trafficking of firearms, 
to strengthen controls for those firearms 
which pose the greatest threat and to 
encourage greater information sharing.
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Tackling specific crime types
Drug driving 
A new offence of driving with a specified drug 
in the body was introduced in March 2015 
with zero tolerance limits for eight illicit drugs, 
as well as risk limits for nine medical drugs. 
The new offence is allowing police to deal with 
drug drivers more effectively since a positive 
blood test is sufficient to secure a conviction. 
As a result we have seen a significant increase 
in drug driving arrests compared to the 
period before the offence came in. Evidence 
suggests that many of those convicted of a 
drug driving offence have committed a number 
of prior offences, suggesting that drug driving 
enforcement may play a role in disrupting or 
uncovering other forms of crime. The THINK! 
campaign to support the new legislation is 
aimed at increasing the belief that drug drivers 
are likely to get caught and convicted and to 
highlight the consequences of a conviction to 
the main target audience of young males. This 
may also act as a deterrent from drug taking 
if the desire to drive outweighs any desire to 
take drugs. We will continue to work closely 
with the police to increase enforcement against 
drug-drivers.
• We will monitor the impact of the 
£1m of funding we have provided to 
police forces in England and Wales in 
2015/16 to support enforcement and 
help them build their capability. This 
includes training more officers in drug 
recognition and impairment testing skills 
to enable more effective and targeted 
enforcement. 
• We intend to explore options for further 
improvements to the drug driving regime 
in 2017/18, including considering 
developing remedial training for drivers 
who have been convicted of driving with 
drugs in the body and implementing a 
High Risk Offender scheme similar to 
the one for drink driving. A pilot remedial 
training course was launched in October 
2016 and ran until the end of April 2017; 
this will help provide evidence for future 
policy developments.
Anti-social behaviour 
The Anti-social Behaviour, Crime and Policing 
Act 2014 introduced new powers which give 
the police, local councils and other frontline 
agencies faster and more effective powers 
to deal with anti-social behaviour. These are 
being used by local areas where appropriate 
to support local action on tackling drug-related 
offending. 
We will:
• work with local areas to encourage 
them to continue to think how best to 
deploy these powers to strengthen the 
protection to victims and communities; 
and  
• develop and share effective practice 
in the use of the powers to support 
local action on tackling drug-related 
offending. 
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Taking a smarter approach to 
drug-related offending
As set out in the Modern Crime Prevention 
Strategy, there is a strong association between 
illegal drugs, particularly heroin and crack 
cocaine, and acquisitive crime. Although 
the numbers of heroin and crack users have 
fallen, there remains an existing cohort of very 
prolific offenders, responsible for around 45% 
of acquisitive offences which equates to more 
than two million Crime Survey offences.50 
There is strong evidence to link drug treatment 
to reductions in offending51 and supporting 
people to address their dependence is 
therefore critical to tackling the risk of 
reoffending. Alongside punitive sanctions, the 
criminal justice system should consider use 
of health-based, rehabilitative interventions 
to address the drivers behind the crime and 
help prevent further substance misuse and 
offending. 
Drug testing on arrest 
We will continue to encourage wider use of 
drug testing on arrest to support police forces 
in monitoring new patterns around drugs and 
crime and provide an early opportunity to refer 
offenders into treatment.  
In addition, we will push for drug testing 
to be more consistently available in the 
community so that it can be readily used as 
part of a community or suspended sentence, 
removing the incentive to impose a custodial 
sentence due to uncertainty of provision in the 
community.
Early intervention
Liaison and diversion services enable offenders 
with mental health, substance misuse and 
other complex needs to be directed towards 
appropriate health interventions from police 
stations or courts. The services also provide 
the police and sentencers with information 
to inform the most appropriate charging and 
sentencing options. 
• Our ambition over the period of this 
Strategy is to build on and expand 
the existing service to ensure fuller 
integration with community mental 
health and substance misuse provision 
to provide interventions for those who 
are subject to a criminal justice sanction, 
particularly for out of court disposals, 
community orders and suspended 
sentences. 
In November 2014, the coalition government 
announced plans for a streamlined framework 
for adult out of court disposals based around 
the community resolution and the conditional 
caution. The new framework would require 
offenders to comply with meaningful conditions 
as part of their disposals or face prosecution 
for the original offence. It would put a much 
greater focus on early intervention with 
offenders to tackle the underlying problems 
that contribute to their offending. For drug 
possession offences, the framework would 
enable individuals to be referred to drug 
treatment workers who would have a range of 
health interventions at their disposal, such as 
brief interventions. The framework could also 
help to refer on those who would benefit from 
more structured treatment.
These measures were piloted by three police 
forces (Staffordshire, West Yorkshire and 
Leicestershire) over a 12 month period. For 
cannabis and khat possession offences, this 
involved the pilot areas using community 
resolutions and conditional cautions instead 
of formal warnings and Penalty Notices for 
Disorder. The pilot finished at the end of 
October 2015 and has been independently 
evaluated. We are considering the findings of 
the evaluation before we announce next steps.
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Increasing the use of treatment as 
part of a community sentence
Those who are going through the criminal 
justice system need adequate access to 
treatment which is proven to help reduce 
reoffending. The Drug Rehabilitation 
Requirement (alongside the Alcohol Treatment 
Requirement and Mental Health Treatment 
Requirement) is available for use by courts 
when imposing a community order and 
suspended sentence order and should be 
applied, where appropriate, and reinforced by 
frequent testing to ensure compliance. 
• We are developing a protocol for drug 
rehabilitation and other treatment 
requirements. The Protocol will 
standardise and improve access to health 
services when treatment is called upon by 
the courts. This will include new maximum 
waiting times from the date of sentence.
Judicial oversight
Community sentences with treatment 
requirements can give courts an alternative 
to custody, taking the most vulnerable and 
chaotic people out of prison and directing them 
instead towards more effective community 
based interventions. In problem-solving courts, 
such as drug courts, judges oversee progress 
in treatment through court-based reviews. 
This means the judiciary taking a central role 
in supporting the offender to turn their lives 
around. The Ministry of Justice is considering 
existing initiatives already developed at a grass 
roots level in the UK.
Prisons 
Drugs cause crime because of the enormous 
profits to be made and the addictions they 
create: this makes them a major challenge to 
the efforts to turn prisoners away from crime 
and the criminal lifestyle. Drugs also cause 
health risks, including a risk of self-harm. They 
cause unpredictable and violent behaviour, 
put pressure on families to supply them and 
form the basis of a trade which involves debt, 
intimidation and violence.
Some organised criminals continue to offend 
whilst in prison and present a continued risk 
outside the prison estate, particularly in regard 
to drug trafficking. Research by the NCA into 
organised crime groups involved in drugs 
trafficking facilitated by an individual in prison 
found illicit mobile phones are a common factor 
and a key enabler for serious and organised 
criminals to continue their involvement in crime.52
As set out in the Prison Safety and Reform 
White Paper53 the use and trade of illegal drugs 
now has a foothold across the prison estate. In 
July 2016, in his first annual report, HM Chief 
Inspector of Prisons Peter Clarke described 
the ‘unpredictable and extreme … dramatic 
and destabilising’ effects of psychoactive 
substances in prisons, which in his view has 
contributed in ‘large part’ to the violence in our 
prisons. 
We are embarking on the most far-reaching 
prison reforms for a generation. These reforms 
will transform how our prisons are run and will 
support prisoners towards rehabilitation and give 
them the skills they need to lead productive, 
law-abiding lives when they are released. Prison 
governors will have more powers and more 
responsibilities for running their prisons and will 
be able to make decisions that are best suited 
to the needs of offenders in their prison. As part 
of this, governors will work in partnership with 
health commissioners to co-commission health 
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services, including drug treatment programmes, 
that address the needs locally. Governors will 
work closely with local health commissioners 
and clinical experts to provide services and will 
be involved in the decision making process at 
each stage of the commissioning cycle. This will 
be based on principles of partnership working, 
evidence-based care, integrated services, clear 
and effective accountability and governance and 
patient-focussed services. We will be supporting 
governors to develop the capability they need 
to understand the commissioning decisions 
they make and ensure they receive the best 
outcomes. Governors will be held to account 
for these outcomes, and we will introduce 
measures of success for health outcomes, 
including substance misuse.  
A range of measures is already in place to 
address the challenge of drugs in prison. 
For example, we have trained over 300 drug 
detection dogs to identify NPS concealed 
in parcels and on people, and introduced 
nationwide mandatory testing for specified 
NPS in prisons. We have made the possession 
of any psychoactive substances in any 
custodial institution a criminal offence under 
the Psychoactive Substances Act 2016. In 
2016, PHE published the NPS in prisons 
toolkit54 to support prison based staff in 
responding effectively to the increasing 
challenge presented by psychoactive 
substances. This was followed up with a 
national training programme consisting of 32 
sessions attended by over 650 custodial and 
healthcare staff. We continue to support the 
development of the police-led, multi-partner, 
National Prisons Intelligence Coordination 
Centre and to increase the number of regional 
and local analysts and investigators. This 
enhanced intelligence network will improve the 
identification, management and disruption of 
organised crime threats, including prisoners 
involved in drug smuggling both within and 
outside the prisons estate. 
However, the motivation and ability of prisoners 
and organised crime groups to use and traffic 
illegal drugs has outstripped our ability to 
prevent this trade. We need to redouble our 
efforts to tackle this challenge with the aim of 
eradicating illicit drug use in prisons. 
In part this will involve making better use 
of existing measures. For example, new 
legislation which makes the possession of 
NPS a criminal offence mirrors that for existing 
drugs. Our focus needs to be on working 
across the criminal justice system to enforce 
these new laws. But, more fundamentally, we 
also need to think again about how we alter 
the behaviours and choices of those involved 
in the use or trade of illegal drugs in prisons to 
tackle current and emerging challenges. In his 
July 2016 annual report, Peter Clarke notes 
that  ‘while various aspects of the problem 
are being addressed through, for example, 
criminalising possession of the products 
and the better use of testing and detection 
technologies, the simple fact remains that 
there is, as yet, no overall national strategy 
for dealing with the problem’. We share his 
concern and recognise the need for a more 
strategic approach. 
To improve the response in the short term we 
will strengthen key existing measures to: 
• enhance our drug testing regime, 
supporting governors to enable a more 
extensive drug testing programme, 
increasing the frequency and range of 
drugs tested for. This will better inform 
substance misuse treatment needs, 
making drug treatment more effective. It 
will reduce the health harms to prisoners 
and ensure better continuity of treatment 
on release into the community. It will 
also inform assessments of prisons’ 
performance;
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• legislative change will also add 
psychoactive substances to the list 
of items that are a criminal offence to 
smuggle into prison, which could mean 
a prison sentence of up to 10 years for 
those found guilty;    
• ensure that the perimeters of prisons are 
secure and maintained in a state that 
can help deter items from being thrown 
into the prison;
• improve our searching capability with 
dedicated search teams that can be 
deployed to target specific problem 
areas including staff searching at 
unpredictable times;
• reduce the opportunity and 
attractiveness for visitors to smuggle 
drugs to prisoners; and
• continue to pursue and evaluate 
technology that can detect drugs, 
including body scanners and drug trace 
detectors.
In the longer term, we will fundamentally 
reassess our existing measures for tackling the 
supply and demand for both existing and new 
controlled substances. This will build on the 
work we are already doing with NHS England 
and others to improve substance misuse 
services. For example, in January 2017, PHE 
published the first annual report on individuals 
receiving specialist interventions for drugs and 
alcohol misuse in secure settings in England. 
These statistics will help us understand how 
well treatment is working and provide a 
statistical baseline for future comparisons, as 
well as being a useful tool for policy makers, 
commissioners and service providers. Existing 
measures that we will reassess include:
• the substance misuse treatment 
pathway for prisoners; and how 
services, including peer support, meet 
the treatment and recovery needs of 
offenders; 
• the relationship between substance 
misuse (including alcohol) and other 
issues, such as mental health;
• the role of prison officers. The 
introduction of a new approach to 
supporting offenders presents an 
opportunity for prison officers to play a 
bigger role in the provision of services, 
whilst building more constructive and 
relevant relationships with offenders;
• drug treatment services to and from the 
community;
• options to address the misuse of 
prescribed medicines more effectively;
• research to assess the relative 
effectiveness of our current methods 
to tackle the supply of drugs, to inform 
decisions about where to prioritise our 
resourcing; and
•  implementation of our commitment 
to move to a smoke free environment 
across the whole prison estate in 
England and Wales.
Making better use of local profiles and 
partnerships 
Since November 2014, our development of 
local partnership board arrangements, local 
profiles and action plans has promoted delivery 
of a wide range of multi-agency, partnership 
activity to disrupt and prevent Serious and 
Organised Crime (SOC). In local areas, this 
partnership approach responds to specific 
threats, such as drug trafficking. We also 
share good practice amongst local partners 
though innovative pilots and delivery focused 
products, employing frontline experts to 
build networks of local stakeholders. These 
experts provide mutual assistance to combine 
partners’ powers to increase impact and tackle 
SOC at the local level. In addition, we deliver 
support and advice to partnerships through 
the provision of national best practice, the 
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dissemination of guidance and wider Home 
Office research.
Integrated offender management 
Integrated Offender Management (IOM) brings 
a cross-agency response to the crime and 
reoffending threats faced by local communities 
by managing the most persistent and 
problematic offenders. Drug misusing offenders 
form part of the cohort prioritised under IOM. 
In a voluntary survey, 62% of arrangements 
reported prioritising this offender group.55 
We will work with local IOM arrangements to 
identify and share effective practice to tackle 
drug-related offending.
Heroin and Crack Action Areas
As set out in the Modern Crime Prevention 
Strategy, Home Office research found that 
heroin/crack cocaine use could account for 
at least half of the rise in acquisitive crime in 
England and Wales to 1995 and between one-
quarter and one-third of the fall to 2012, as the 
cohort who started using in the late 1980s and 
early 1990s aged, received treatment, ceased 
using drugs or died.56 Given the changing 
patterns and trends in drug misuse, there is 
always the possibility that a new and younger 
cohort of heroin and crack users could 
emerge. This could lead to a new increase in 
crime, together with wider social and health 
harms and impact on local areas. Local 
partners need to be alert to any changes and 
aware of the potential implications for these 
user groups and work together to reduce the 
harms to individuals and their communities.  
In 2015, the Home Office and PHE piloted 
the first heroin and crack action area 
(HACAA) in Middlesbrough which galvanised 
further collaborative working, including the 
development of a joint strategy to address 
local needs. Following the Bradford HACAA, 
the drugs testing criteria was reviewed and 
there was a 68% increase of referrals to 
treatment services in the first month. The area 
is now focused on those individuals who have 
been in treatment for over six years to better 
understand their complex needs and possible 
links with crime. We will continue to build on 
this approach by: 
• monitoring warning indicators and 
intelligence (e.g. estimates of heroin and 
crack use, price and purity, acquisitive 
crime) to identify key areas which may 
be at risk of experiencing increased 
harms and/or increases in new and 
younger heroin and crack users; and
• bringing local partners in these areas 
together (e.g. local authority, health, 
policing and probation) to focus on 
heroin and crack use and offending in 
their area; ensure there are coordinated 
pathways available to provide 
appropriate support to users; and 
support and stimulate local action to 
tackle the problems posed.
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3. Building Recovery
Progress has been made in supporting people 
to recover from their dependence on drugs, 
but we need to go further. We will raise our 
ambition for recovery by enhancing treatment 
quality and improving outcomes through 
tailored interventions for different user groups. 
We will support local areas to ensure the right 
interventions are given to people according to 
their needs. We will also support local areas 
to deliver an enhanced joined-up approach to 
commissioning and delivery of the wide range 
of services, in addition to treatment, that are 
essential to supporting every individual to live a 
life free from drugs and dependence.
We know recovery is only achievable through a 
partnership-based approach with action taken 
across a range of services, particularly housing, 
employment and mental health. There are clear 
expectations for partners at both a national 
and local level set out throughout this chapter.
Commissioning – structures 
and transparency 
We are clear that no-one should be left behind 
on the road to recovery. Effectively funded and 
commissioned services, targeted at helping 
people fully recover from dependence, is 
crucial to delivering this. 
We have confirmed the continuation of the 
ring-fenced Public Health Grant to local 
authorities until April 2019 which funds 
drug and alcohol services (treatment and 
prevention). During this period we will maintain 
the condition for local authorities to ‘have 
regard to the need to improve the take up 
of, and outcomes from, drug and alcohol 
services’. Our consultation “Self-sufficient local 
government: 100% business rates retention” 
set out proposals to fund public health 
responsibilities beyond this period through 
retention of locally retained business rates. 
As highlighted throughout this Strategy, we 
will also develop a range of measures which 
will deliver greater transparency on local 
performance, outcomes and spend. This 
will build on the Public Health Outcomes 
Framework enabling the public and partners to 
hold local areas to account. 
Through the Life Chances Fund, up to £30m 
has been committed to support innovative 
solutions focused on tackling drug and 
alcohol dependence. The Fund will pay for 
outcomes successfully delivered through 
social impact bonds. Since it launched in 
July 2016, the Fund has supported the 
continued development of 12 drug and alcohol 
dependency projects. A final decision on which 
of the fully developed proposals will be funded 
will be taken by September 2017. 
A further £10 million has been announced for 
outcomes payments, including those relating 
to substance misuse, for long-term rough 
sleepers or single homeless people, as part 
of the Homelessness Prevention Programme. 
This group represents some of the most 
vulnerable in society.
The ACMD has been looking at the 
commissioning of drug treatment and 
recovery services and the impact this can 
have on recovery outcomes for individuals and 
communities. We look forward to receiving 
this advice and will carefully consider any 
recommendations to inform future policy.
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Close collaboration, partnerships and 
alignment 
Locally led recovery systems require close 
collaboration and effective partnership 
working to deliver the full range of end-to-
end support for those with drug and alcohol 
problems. Drug (and alcohol) treatment in 
the community is commissioned by local 
authorities which are ideally placed to 
coordinate drug treatment services with 
broader services provided, including the 
housing and homelessness sector, children’s 
services, and social care. Treatment services 
also need to improve collaboration with mental 
and physical health care; employment services 
provided by Jobcentre Plus and contracted 
provision, including the new Work and Health 
Programme; the criminal justice system, and 
notably providing care “through the gate” to 
those patients leaving prison; and all relevant 
community services and groups e.g. domestic 
abuse services. 
The Health and Social Care Act 2012 requires 
the full breadth of local partners to be 
represented in local priority decision-making. 
Health and wellbeing boards are an example of 
an important mechanism in this process. They 
are ideally placed within local communities 
to bring together key partners to deliver 
better outcomes for individuals, including 
the most vulnerable, and there is great 
potential for further joint working. Inclusion of 
representatives from the local police force or 
criminal justice agencies can enable boards 
to take a broader strategic view of their area 
beyond health and social care. Joint Strategic 
Needs Assessments provide boards with the 
opportunity to better understand the nature of 
public needs and demands on local services, 
which can in turn influence local commissioning 
strategies. We will work with the Department 
of Health to ensure that there is appropriate 
representation from both sectors on health and 
wellbeing boards so that we can fully realise 
the benefits of closer collaboration between 
policing and health partners. 
There is a well-established evidence base 
and authoritative clinical guidance57 on what 
constitutes effective drug treatment. The 
2007 Clinical Guidelines have been updated 
and will be published alongside this strategy. 
Commissioning and contracting should be 
informed by robust service user involvement and 
local clinical expertise. To support this, we will:  
• encourage more effective, joined up 
commissioning by enhancing the 
transparency of local action with a 
broader set of measures and indicators, 
setting out joint responsibility for 
outcomes where appropriate e.g. 
drugs and mental health, drugs and 
employment, drugs and the criminal 
justice system, drugs and housing;
• bring PHE support to local areas to 
ensure delivery is joined up, access to 
wider services is available, and the best 
possible outcomes are being achieved;
• share guidance and best practice of 
effective commissioning across multiple 
agencies; and 
• make data on outcomes against 
the new, broader set of indicators 
publicly available and easily accessible 
and provide clear and accurate 
information on how much local areas 
spend on treatment for dependence 
(disaggregated by drugs and alcohol, 
treatment and prevention, and adults 
and children/young people).
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Local regulation and quality assurance 
We are clear that local drug (and alcohol) 
treatment commissioners should assure 
themselves that the services they commission 
are safe and effective at improving individuals’ 
health and helping people recover from drug 
dependency.
Commissioners should support and develop 
quality governance structures for drug 
treatment. The governance structures must be 
clearly linked to local safeguarding procedures 
for children and vulnerable adults and give 
consideration to the specialist nursing and 
medical care that some service users require. 
Compliance with relevant clinical guidelines is 
also a vital component of quality governance. 
It is especially important that commissioners 
seek these assurances for residential 
treatment, particularly detoxification, 
commissioned on a spot-purchase or block 
contact basis. Where supported housing is 
commissioned, they should assure themselves 
that the quality and type of support and 
accommodation provided is appropriate to 
client needs. Commissioners should also 
assure themselves that all substance misuse 
services are appropriately registered with the 
Care Quality Commission, if they provide a 
regulated activity. 
In addition to contracting mechanisms and 
outcome monitoring, commissioners should 
refer to service user and local provider/clinician 
feedback, in addition to the Care Quality 
Commission’s reports, to identify and address 
any concerns about service quality.
Re-tendering has frequently been an effective 
mechanism by which some commissioners 
have stimulated the market, promoted 
innovation and increased the accountability 
of services. However, the process can 
be complex and can generate unplanned 
consequences and instability with long-lasting 
effects e.g. high staff turnover, loss of trust 
and relationships. While local areas must 
remain compliant with relevant regulations, 
commissioners have a broad range of other 
mechanisms at their disposal to enhance 
quality and outcomes, such as performance 
management and collaborative approaches to 
improvement, that do not require re-tendering.
Workforce 
Treatment service commissioners need to be 
sure that the services they commission have a 
workforce which is competent, motivated, well-
led, appropriately supervised and responsive 
to new challenges. It is important that services 
have the resources and capacity to train and 
develop their workforce, including new and 
existing clinicians. We will support this by:
• working with Health Education England, 
commissioners and providers to ensure 
the development and retention of the 
workforce, ensuring quality and safety of 
services and the outcomes; and
• working with the Royal Colleges and 
other professional bodies to produce 
and promote guidance on the specific 
roles of clinicians and other frontline 
workers, as well as supporting the 
availability of relevant training.
Service user involvement
Service user involvement in the design and 
delivery of services and recovery systems 
can contribute significantly to the evolution of 
effective drug and alcohol treatment systems. It 
is important that service users have a full stake 
in the decision-making process about how 
their needs are met. 
• Local areas, with PHE support where 
needed, should engage service users 
in the implementation of this Strategy at 
both system and service levels. 
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Recovery systems
Treatment 
Our country has a world-leading drug and 
alcohol treatment system, with a solid body 
of international evidence and national clinical 
guidance to inform it. The update to Drug 
Misuse and Dependence: UK Guidelines on 
Clinical Management focuses on providing 
high quality advice on pharmacological and 
psychosocial interventions known to be 
effective.
The expert working group of clinicians that 
developed the guidance looked at aspects of 
practice known to enhance recovery from drug 
dependency, including: 
• planning and reviewing integrated and 
coordinated pathways of care; 
• a stronger emphasis on a holistic, 
recovery-oriented approach; 
• tailoring interventions; 
• the appropriate use of regular drug 
testing; 
• the competencies needed by staff to 
tackle a broad range of new and existing 
drug misuse and dependence issues; 
• wider healthcare issues, especially blood 
borne viruses and overdose; 
• maintaining safety for drug service users 
and their children;
• ensuring equitable treatment in different 
settings across the country, including 
criminal justice settings; and
• addressing education, training, housing 
and employment as core aspects of the 
recovery journey.
There is also a range of clinical guidance 
to support more specific issues, including 
the evidence-based clinical guidelines 
produced by Project NEPTUNE, funded by 
the Health Foundation, to aid in the detection, 
assessment and management of NPS users.58 
This is aimed at clinicians working in a range 
of frontline settings, such as hospitals, sexual 
health services, primary care and drug 
treatment services.
• We will support and promote NEPTUNE 
II, a national on-line learning programme 
for frontline workers designed to 
improve the detection, assessment 
and management of the acute and 
chronic harms associated with the use 
of NPS and club drugs, and to increase 
delivery of evidence-based interventions. 
National rollout of NEPTUNE II is 
planned for later in 2017, alongside a 
formal evaluation.
It is also vital that support is available after 
people have completed structured treatment 
to help them continue their recovery journeys, 
building on the progress they have made. 
Local areas should ensure that recovery 
support interventions, as defined in the 
National Drug Treatment Monitoring System, 
are available from the start of structured 
treatment and after it is completed. Services 
should also provide for rapid re-entry to 
treatment should it be needed.
Effective data sharing
In 2016, the Ministry of Justice and PHE 
matched information on offenders to their 
participation in drug and alcohol treatment 
programmes. 
• This new data share will enable us to 
better understand the links between 
dependent drug (and alcohol) use 
and offending careers, how treatment 
impacts on levels of reoffending for 
different cohorts of people who use 
drugs, and ensure that interventions for 
offenders are targeted where they will be 
most effective. 
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Treatment: from custody to community 
As part of our work to reform prisons 
and enable governor leadership, we have 
committed to looking at how to move to a 
joint approach to commissioning of health 
services, including drug and alcohol treatment, 
in prisons. This aims to give governors more 
control and accountability over the services and 
treatments in their prison, and ensure continuity 
of treatment with services in the community.
To support commissioners’ and governors’ 
decisions about effective services, NHS 
England is introducing the Health and Justice 
Information System. This will provide robust 
measures against which to evaluate the 
effectiveness of drug treatment systems 
in custodial settings. The Integrated Drug 
Treatment System evaluation demonstrates the 
protective impact of opioid substitution therapy 
in preventing drug related deaths post release.
• We will use this data and learning to 
identify and disseminate good practice 
to contribute to improved outcomes in 
relation to prison-based drug treatment 
and the prevention of drug related 
deaths.
We are working with local commissioners to 
develop community-based health treatment 
pathways. These mean that offenders can 
access appropriate treatment at any point of 
their journey in the criminal justice system – 
from the police station through community 
sentences and after release from prison.
Physical and mental health
Drug misuse is often accompanied and 
complicated by physical and mental health 
problems. Local and custody-based treatment 
systems need interventions to help prevent 
these problems and, where they do occur, 
coordinated and integrated pathways of care 
are needed to treat them.
Specific advice is set out in the updated Drug 
Misuse and Dependence: UK Guidelines 
on Clinical Management. Key to supporting 
improved health is action to prevent blood 
borne infections by vaccination (where 
available) and by maintaining the availability of 
injecting equipment through needle and syringe 
programmes, including through non-drug 
specialist outlets such as sexual health clinics. 
Infections like hepatitis C and TB should be 
identified via regular and repeated offers of 
testing, and infections like hepatitis C should 
be treated through coordinated services.
Drug overdoses can be prevented by ready 
access (and return) to drug treatment60 and 
by overdose awareness and response training 
for people who use drugs and their families. 
Heroin-related deaths can also be prevented 
by the provision of naloxone61 and all local 
areas should have appropriate naloxone 
provision in place. 
Deaths from drug misuse have risen since 
2014 to the highest levels ever recorded. PHE 
has a programme of analysis and other work 
to better understand these deaths and how 
future premature deaths might be prevented. 
After the reported rise in 2015, PHE and the 
Local Government Association convened an 
independent inquiry into the causes of these 
increases and their prevention. Although finding 
that the causes of the increases were multiple 
and complex, the inquiry’s report concluded 
that the dramatic recent rise has been caused 
primarily by a rise in the availability of heroin after 
the shortage of late 2010-early 2011.62 But it 
added that there is also a longer-term, underlying 
increase primarily caused by a cohort of heroin 
users getting older, more ill and who are more 
susceptible to overdose death. Other factors 
include increases in the number of deaths 
involving women, NPS, prescription medicines, 
and suicide. The inquiry predicted further rises 
from the primary factors and described the need 
for further action at all levels of the system.
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The inquiry recommended actions for local 
commissioners and providers, as well as 
other services across social care, housing and 
criminal justice. These actions are all aligned 
with our core principles:
• to enable a coordinated, whole-system 
approach to meet the complex needs 
of people who use drugs including 
better access to physical and mental 
healthcare, particularly for older users;
• to maintain the personalised and 
balanced approach to drug treatment 
and recovery support recommended 
by national drug strategies and clinical 
guidance;
• to maintain the provision of evidence-
based, high-quality drug treatment and 
other effective interventions;
• to reach out to those not currently in the 
treatment system; and
• to ensure that the risk of drug-related 
death is properly assessed and 
understood, and eliminate poor practice 
that could increase risk.
The ACMD has also reported on reducing 
opioid-related deaths63. We have reviewed 
this advice and its recommendations 
carefully, and will respond separately to the 
recommendations. 
Smoking is also highly prevalent among 
alcohol and drug misusing populations, and is 
a significant contributor to illness and death. 
Drug treatment services should work with 
local stop smoking services to offer smoking 
cessation to all, and harm reduction for people 
unable or unwilling to stop smoking.
Drug misuse is common among people with 
mental health problems: research indicates 
that up to 70% of people in community 
substance misuse treatment also experience 
mental illness64, and there is a high prevalence 
of drug use among those with severe and 
enduring conditions such as schizophrenia and 
personality disorders65. 
We know that people with co-occurring 
substance misuse and mental health 
conditions are too often unable to access 
the care they need. For example, substance 
misuse services may use mental health 
conditions as an exclusion criteria, and vice 
versa, and there is a lack of coordination 
between drugs and mental health, with 
services being too focused on one primary 
need. People with co-occurring mental health 
conditions are particularly at risk of dying by 
suicide. Between 2004 and 2014 one third 
(33%) of patients in mental health treatment 
who died by suicide had a history of drug 
misuse, but only 7% were in contact with drug 
treatment services66. Despite this heightened 
risk, it is common to hear reports of people 
experiencing mental health crisis being turned 
away from services due to intoxication, without 
plans to engage them. We are committed 
to improving the co-ordination of mental 
health services with other local services, 
including police forces and drug and alcohol 
rehabilitation services. To tackle this we will:
• work with PHE and NHS England to 
publish new national guidance which 
supports local areas to effectively 
collaborate across drug, alcohol and 
mental health services, preventing 
exclusion based on presenting need, 
to meet obligations in the Five Year 
Forward View for Mental Health67 and 
the Crisis Care Concordat 68;
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• improve the data to enable providers 
and commissioners to better understand 
the scale of unmet need, and to monitor 
impact; and 
• work with Health Education England and 
other stakeholders, in line with the Five 
Year Forward View for Mental Health 
recommendation, to support development 
of an appropriately trained and competent 
workforce to meet the needs of people 
with co-occurring substance misuse and 
mental health conditions.
Peer-led recovery support
Peer support is an essential component 
of effective recovery and should be easily 
accessible before, during and after formal 
structured treatment.69 Evidence for the 
efficacy of mutual aid is well-documented 
and peer support is highly valued; both can 
increase and sustain the gains achieved by 
formal treatment, in addition to challenging 
stigmatising views of people who use drugs. 
• PHE will continue to develop, promote 
and support the implementation of its 
Mutual Aid Toolkit.
• PHE will explore the potential of online 
mutual aid groups, which can be a vital 
support mechanism particularly for 
those in sparsely populated rural areas, 
and support their development in line 
with evidence. 
Other visible and innovative service-user led 
initiatives include peer mentoring for those 
engaged in treatment services, training for 
those working with drug users and community 
initiatives such as recovery cafés.
• Local areas should support community-
based initiatives which promote and 
sustain recovery, including those that 
meet the needs of families themselves 
or include them in their family member’s 
recovery process.
Employment and meaningful activity 
Access to employment and meaningful 
activity is a critical element of recovering from 
substance misuse and dependence and 
sustaining recovery, and recovery is a key step 
in supporting individuals into employment.70 
Welfare reforms since 2010, (e.g. Universal 
Credit and the Work Programme) have 
provided opportunities for local innovation, 
new partnerships and tailoring of services 
for claimants dependent on drugs, but there 
is much more that can and should be done. 
Moving forward, we want individuals to 
engage in a range of meaningful activities, 
such as volunteering, education and 
training, to enhance skills, gain experience 
and confidence, and ultimately move into 
employment if they are able to. Building trust 
is critical to identifying dependency-related 
needs. It is particularly important for services 
(e.g. treatment and public employment 
services) to work together and learn from 
good practice so that people feel confident 
in disclosing their drug misuse without fear 
of judgement or benefit sanction, and so that 
public employment services can better identify 
substance misuse and remove the need for 
clients to broach a difficult subject.
The Government asked Dame Carol Black to 
conduct an evidence-based review into the 
labour market challenges faced by those with 
drug and/or alcohol misuse issues when they 
seek to enter, return to and/or remain in work. 
Dame Carol consulted widely and her report, 
“An Independent Review into the impact on 
employment outcomes of drug or alcohol 
addiction, and obesity”, was published on 
5 December 201671. We have responded to 
some of the recommendations in Improving 
Lives: Helping Workless Families, published on 
4 April 201772. In addition we will: 
2017 Drug Strategy
35
• continue the roll out of Universal Credit, 
coupled with changes to the work 
coach role to support claimants as they 
progress towards work, and once they 
start employment;
• continue transforming the role 
Jobcentres play at the heart of local 
communities and partnerships, learning 
from the Universal Support approach 
in Universal Credit to provide effective, 
joined-up support that tackles multiple 
and complex barriers to employment, 
including substance misuse – a key 
commitment within Improving Lives: 
Helping Workless Families;
• introduce the new Work and Health 
Programme in 2017 which will provide 
intensive and tailored support to 
people with a disability and the long 
term unemployed and will include early 
access for priority groups such as 
people with a drug dependency so they 
can get additional support at any point 
in their claim; and
• continue the ‘See Potential’ campaign 
launched in 2015 to encourage  
employers to recruit more people from 
disadvantaged groups, including those 
recovering from drug and alcohol 
dependence, by highlighting the 
business benefits.
Housing and homelessness 
Stable and appropriate housing is crucial 
to enabling sustained recovery from drug 
misuse; and sustained recovery is essential 
to an individual’s ability to maintain stable 
accommodation.73 
Lankelly Chase research into severe and 
multiple disadvantage estimated that at least 
58,000 people a year have contact with 
homelessness services, substance misuse 
services and the criminal justice system, at an 
approximate cost of £21,180 per person per 
annum.74 We are helping local councils and 
developers work with local communities to plan 
and build better places to live for everyone. 
This includes building affordable housing, 
improving the quality of rented housing, and 
helping people to buy a home. Our affordable 
homes programme also makes funding 
available for supported housing for vulnerable 
people, for example those with substance 
misuse problems. To address this we: 
• have increased central investment 
for innovative programmes to tackle 
homelessness to £149m until the end of 
the spending review period.
• will explore how we can secure better 
outcomes for those with complex needs 
(such as substance misuse, mental 
health and homelessness), including 
consideration of innovative approaches 
such as the Housing First model, 
building on the existing projects75 in a 
number of areas across the country and 
supporting new manifesto commitments 
to pilot a Housing First approach to 
tackle rough sleeping; 
• will improve our national and local data 
on homelessness and rough sleeping, 
to help us better understand the current 
level of need, and evaluate what works 
in achieving positive outcomes for this 
group;
• will learn from the £50m homelessness 
prevention programme in which 84 
projects will focus on new initiatives to 
prevent homelessness, act quickly to 
support people who are at risk of or new 
to rough sleeping, and help long-term 
rough sleepers with the most complex 
needs;
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• will work with treatment providers, the 
homelessness sector and housing 
support services to identify and share 
best practice to support local authorities 
in identifying routes into appropriate 
accommodation for those recovering 
from a drug dependency; and
• will work across the whole supported 
housing sector, including drug and 
alcohol services, to develop the detail 
that underpins the new funding model 
for housing costs for supported housing. 
We announced a new funding model 
on 15 September 201676 and a formal 
consultation ran for 12 weeks, closing on 
13 February 2017. We are taking stock 
of the responses to the consultation and 
the joint DCLG/DWP Select Committee 
report which was published over the 
election period and will set out further 
details on next steps shortly.77 
Families 
Parental drug misuse can have a significant 
impact on children’s outcomes. Families and 
carers can also play a key role in supporting 
recovery, which is often unrecognised, and 
can enhance outcomes. Family members and 
carers also have their own support needs. 
• PHE will develop a toolkit for local 
authorities to support local responses 
to parental substance misuse, which 
will include local prevalence data on 
parental/carer use, the associated 
harms and likely costs, guidance and 
information on effective interventions.
• Evidence-based psychological 
interventions which involve family 
members should be available locally 
and local areas should ensure that 
the support needs of families and 
carers affected by drug misuse are 
appropriately met.
Measuring outcomes 
Measuring recovery is complex. The 2010 
Strategy put recovery at its heart and 
measured success based on the numbers 
coming out of treatment and being free from 
dependence for six months. While this sent 
an important message to the sector, and 
more adults are leaving treatment successfully 
compared to 2009-1078, there is further to 
go. The following measures clearly set out 
our expectations for local commissioners 
and delivery partners, and progress across 
all domains will be considered as part of the 
Home Secretary chaired Board. The Board will 
consider how to support commissioners and 
delivery services to integrate these measures.
To support our overall ambition to increase 
rates of recovery from dependence we will:
• expand the measure to capture those 
sustaining freedom from all dependency 
for twelve months (not just six); 
• segment this data to provide a better 
picture of the treatment population 
and track progress for those for whom 
evidence tells us we can expect even 
higher recovery rates79 (e.g. newer 
opiate users and non-opiate users); and
• provide a breakdown of local and 
national treatment penetration rates 
and time taken to access treatment to 
ensure that we are reaching those who 
need support.
Given the cross-cutting nature of recovery, we 
will develop a framework of joint measures, 
improving outcomes across key domains 
that are integral to achieving and sustaining 
recovery and promoting the integrated systems 
required to achieve this locally:
• homelessness and housing – a 
joint outcome measure between 
homelessness/housing support services 
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and drug and alcohol treatment 
providers to ensure that appropriate 
housing and housing-related support is 
given to those who need it; 
• crime and offending – a joint outcome 
measure with relevant criminal justice 
partners to understand the support 
provided to drug-misusing offenders and 
its impact on reoffending; 
• mental health – a joint outcome 
measure for individuals who have co-
occurring mental health conditions; and
• employment – a joint outcome measure 
between public employment services 
and drug and alcohol treatment 
providers, and other associated 
measures which give more consideration 
to distance travelled towards the labour 
market e.g. volunteering, training and 
meaningful activity.
We will capture the impact of wider health and 
social care costs and harms associated with 
drug misuse, including:
• hospital admissions related to drug 
misuse; 
• rates of blood borne viruses; and 
• numbers of drug-related deaths, 
including on release from prison. 
We will support local partners to measure 
outcomes from key processes which promote 
recovery, including:
• the proportion of clients facilitated to 
access mutual aid or peer support;
• other recovery support interventions, 
such as housing, employment or 
parenting support as defined in the 
National Drug Treatment Monitoring 
System, provided before, during and 
after treatment; and
• the rate of individuals either discharged 
successfully from treatment following 
release from prison or picked up in the 
community within three weeks of release.
Stronger governance and 
accountability
To oversee delivery of the entire Drug Strategy, 
drive action across Government and our 
partners and hold different elements of the 
system to account, we will establish a new 
Drug Strategy Board, chaired by the Home 
Secretary. This will include representation from 
all the key Government departments and wider 
partners, e.g. Public Health England and the 
National Policing Lead on Drugs. 
The Board will use greater transparency and 
data on performance to support action by local 
services to deliver the best possible outcomes 
and monitor progress. PHE will also support 
local areas to implement evidence-based 
interventions and target its efforts toward those 
areas whose performance is furthest from what 
may be expected.
We will also appoint a national Recovery 
Champion. This individual will sit on the Board 
and report back on their role to:  
• provide a national leadership role around 
key aspects of the recovery agenda 
that support sustained recovery, in 
partnership with PHE;
• support collaboration between local 
authorities, public employment services 
and the Health and Work Programme, 
housing, criminal justice agencies, and 
other partners;
• seek to address the stigma faced by 
people with drug or alcohol dependency 
issues; and
• act as a ministerial envoy visiting 
different communities, providers and 
local recovery champions.
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To support our ambition for enhanced 
governance and accountability, the Care 
Quality Commission will play a vital role in 
assuring the quality of regulated services, 
supplementing local quality governance 
mechanisms. It continues to enhance its 
capacity in relation to substance misuse 
services: developing its expertise; providing 
more training and support to its inspectors; 
and improving intelligence on services. This 
includes greater engagement with, and access 
to data from, PHE to enable the development 
of indicators to inform the Care Quality 
Commission’s monitoring and inspection of 
substance misuse services. 
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4. Global Action
The United Kingdom is a global leader 
in tackling drug harms. It is in the United 
Kingdom’s interest to promote a balanced 
approach internationally; reducing the global 
supply and demand for drugs helps us to 
minimise drug harms at home. 
We will strengthen international cooperation, 
and work with partners to deliver a balanced, 
evidence-based response. Alongside the 
upstream supply reduction work detailed in 
chapter two we will shape the international 
debate on drugs, respond to new threats and 
use our global networks to share the latest 
evidence.
While the United Kingdom is a member 
of the European Union we will remain fully 
engaged with European partners, including 
the European Monitoring Centre for Drugs 
and Drug Addiction. We will continue to work 
closely with European and other international 
partners once the United Kingdom leaves the 
European Union.  
Shaping international policy 
and practice
United Nations General Assembly 
Special Session on Drugs
The United Kingdom used the United Nations 
General Assembly Special Session on Drugs 
in April 2016 to enhance cooperation and to 
share best practice on delivering an effective 
approach with the United Nations drug 
conventions. We will work with international 
partners to implement the commitments made 
in the ‘Outcome Document’ which was agreed 
by United Nations Member States at the Special 
Session. Our priorities in this area will be to:
• enhance international action on new 
psychoactive substances;
• champion a proportionate criminal 
justice response that includes smart 
targeted action at each stage of the 
criminal justice process;
• promote the integration of efforts to 
tackle drug harms with the Global Goals; 
and
• strengthen cooperation between United 
Nations agencies and international 
organisations while maintaining the 
central leadership, coordination and 
facilitation roles of the United Nations 
Commission on Narcotic Drugs and 
the United Nations Office on Drugs and 
Crime. 
Global leadership on new 
psychoactive substances
The United Kingdom is leading the global 
response to NPS. Steering international 
action, such as law enforcement cooperation 
against the supply of these substances, helps 
us to reduce their harms at home. We are 
implementing a long-term plan to meet the 
challenges these substances present, including 
securing the first ever control of a NPS, 
mephedrone, under the United Nations drug 
conventions. Significant progress has been 
made in recent years, but there is more to be 
done.
We will strengthen the international response to 
NPS through:
• Data collection: we will collect and share 
information from the UK Focal Point early 
warning system network with international 
partners to enrich our understanding of 
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NPS. This includes sharing data on the 
emergence, use and harms of these 
substances, and sharing analytical data 
to support forensic identification.  
• International control: we will work 
with the World Health Organisation, the 
United Nations Office on Drugs and 
Crime and others to ensure international 
controls on the most harmful substances. 
• Law enforcement cooperation: we 
will strengthen cross-border law 
enforcement action on the supply 
of NPS, including by stepping up 
engagement with the source countries 
of these substances.
• Policy exchange: we will use our 
international networks to share best 
practice from the United Kingdom. This 
will include our experience of tailored 
prevention and treatment responses, 
such as Project NEPTUNE80. 
A global research and analysis network
We will use our global networks to share the 
latest evidence with international partners. This 
will include: 
• working with international organisations 
to tackle emerging issues, such as novel 
synthetic opioids, and evolving markets 
for NPS;
• promoting the work of the ACMD in 
international fora; 
• supporting transnational research. 
For example, we are a partner in the 
European Research Area Network 
on Illicit Drugs (ERANID), funding the 
UK arm of three major transnational 
research projects; and
• monitoring the impact of policy 
developments overseas. 
Wider cross-government objectives
We will also support a range of international 
cross-government objectives that overlap with 
this Strategy. Our priorities are to reduce the 
transmission of HIV/AIDS, increase access 
to controlled medicines, and promote human 
rights.    
Reducing the transmission of HIV/AIDS
Significant progress has been made in the 
global response to HIV, but we cannot afford 
to be complacent. We are deeply concerned 
that HIV transmission among people who inject 
drugs in low and middle income countries 
remains alarmingly high. Between 2011 and 
2015 new HIV infections among people who 
inject drugs increased by a third, accounting 
for more than 40% of new infections in some 
countries81.
To address HIV infections in people who inject 
drugs in low and middle income countries, we 
will:
• advocate a public health approach that 
respects human rights and addresses 
stigma and discrimination;  
• support the comprehensive package 
outlined in the World Health 
Organisation’s 2014 Consolidated 
Guidelines on HIV prevention, 
diagnosis, treatment and care for key 
populations.82 This includes needle and 
syringe programmes, opioid substitution 
therapy and access to anti-retro viral 
treatment for people who inject drugs. 
We will continue to urge all countries 
facing significant HIV infections amongst 
people who use drugs to adopt this 
package; and
• follow and support the clear guiding 
principles towards ending AIDS by 2030 
as set out in the UNAIDS 2016-2021 
strategy83.
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We are proud to be the second largest 
international funder of HIV prevention, care 
and treatment. We will continue to be a voice 
for this as the international community moves 
toward the implementation of the Global Goals.
Increasing access to controlled medicines
The United Nations drug conventions are 
founded on the dual goals of reducing the illicit 
use of dangerous substances and ensuring 
access to controlled substances for medical 
purposes.  Despite this, up to 5.5 billion people 
live in countries with low or non-existent 
access to controlled medicines.84 As a result, 
too many people live and die in avoidable 
pain. We will improve the access of the world’s 
poorest to essential medicines by: 
• working with the World Bank, the 
World Health Organisation, the Gates 
Foundation and the New Partnership 
for Africa’s Development to strengthen 
health systems in the poorest countries; 
• promoting a stronger, evidence-based 
approach to the prescribing and 
dispensing of medicines; and
• funding the Medicines Transparency 
Alliance, which promotes greater 
transparency of pharmaceutical systems 
in developing countries. 
Supporting countries to strengthen their 
health systems will remain a top priority for the 
Department for International Development’s 
health work.  
Promoting human rights
The United Kingdom has a proud history 
of delivering our human rights obligations, 
including guaranteed access to treatment, 
measures to reduce the harms of drug use 
and proportionate criminal justice responses. 
We also have a strong record of championing 
human rights internationally, and will continue 
to use our networks to advocate for drug 
policies across the world to place human rights 
at their core. This will include:
• lobbying international partners to widen 
access to treatment and implement 
proportionate criminal justice responses;
• opposing the use of the death penalty 
in all circumstances as a matter of 
principle. We will urge all governments 
who use the death penalty for drug 
offences to abolish this unacceptable 
practice; and
• holding the international agencies we 
fund to account for compliance with 
their human rights obligations.
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Conclusion and next steps
We will continue to take a balanced approach 
to tackling drug misuse to ensure that fewer 
people use drugs in the first place and to 
support those who do to stop and live a life 
free from drugs and dependence. This cross-
cutting and ambitious Strategy sets out our 
expectations for action at all levels through a 
collaborative and partnership-based approach, 
which is essential to tackling the problem in all 
its dimensions.  
We recognise the challenges ahead in relation 
to an ageing and harder to help cohort of 
heroin users, in addition to changes in the way 
funding and services will be provided. However 
this also represents new opportunities for local 
areas to embrace a coordinated response to 
drug misuse which will reduce crime, improve 
life chances, promote better health and protect 
the most vulnerable in our communities. 
We will continue to consider the evidence and 
monitor emerging threats and patterns of use 
to ensure we are able to take an agile and 
evidence-based response to the problem. 
We will undertake a series of events to 
promote the Strategy and our ambitions, 
engaging with the wide range of partners 
needed to deliver this cross-cutting approach. 
By working together, we can achieve a safer, 
healthier society, one that works for everyone 
and in which every individual is supported to 
live a life free from drugs and enjoy a brighter 
future for themselves and their families. 
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